Detalhe da pesquisa
1.
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
Circulation
; 144(22): 1750-1759, 2021 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34706555
2.
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
Circulation
; 144(23): 1845-1855, 2021 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34710343
3.
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
Circulation
; 143(1): 33-44, 2021 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33148016
4.
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
N Engl J Med
; 380(1): 11-22, 2019 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30415628
5.
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.
Circulation
; 141(5): 367-375, 2020 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707829
6.
Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE).
Am Heart J
; 235: 54-64, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33516752
7.
Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol.
Diabetes Obes Metab
; 21(2): 366-371, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30225881
8.
Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis.
Lipids Health Dis
; 18(1): 175, 2019 Sep 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31526399
9.
Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins.
Front Cardiovasc Med
; 9: 982815, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36407462
10.
Global assessment improves risk stratification for major adverse cardiac events across a wide range of triglyceride levels: Insights from the KP REACH study.
Am J Prev Cardiol
; 9: 100319, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35199077
11.
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
J Am Coll Cardiol
; 79(17): 1660-1671, 2022 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35483753
12.
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
J Am Heart Assoc
; 11(6): e022937, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35261279
13.
Real-world analyses of patients with elevated atherosclerotic cardiovascular disease risk from the Optum Research Database.
Future Cardiol
; 17(4): 743-755, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33275042
14.
Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study.
J Am Heart Assoc
; 10(20): e020377, 2021 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34622663
15.
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
J Am Coll Cardiol
; 78(15): 1525-1537, 2021 10 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34620410
16.
Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007-2014.
Am J Prev Cardiol
; 3: 100087, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34327466
17.
REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES]).
Am J Cardiol
; 134: 62-68, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32933754
18.
Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007-2014.
Cardiol Ther
; 9(1): 207-213, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32328971
19.
Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] Trial).
Am J Cardiol
; 132: 36-43, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32773223
20.
The association between triglycerides and incident cardiovascular disease: What is "optimal"?
J Clin Lipidol
; 14(4): 438-447.e3, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32571728